Open AccessRising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II—An Updated Analysis of SEER-Medicare Data
Author(s) -
Ya Chen Tina Shih,
Chun Ru Chien,
Bumyang Kim,
Yu Shen,
Liang Li,
Daniel M. Geynisman
Publication year - 2019
Publication title -
pharmacoeconomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.809
H-Index - 100
eISSN - 1179-2027
pISSN - 1170-7690
DOI - 10.1007/s40273-019-00824-2
Subject(s) - medicine , renal cell carcinoma , incidence (geometry) , epidemiology , activity based costing , cohort , socioeconomic status , indirect costs , health economics , surveillance, epidemiology, and end results , emergency medicine , public health , demography , environmental health , cancer registry , population , pathology , physics , accounting , marketing , sociology , optics , business
The influx of new oncologic technologies has changed the treatment landscape of renal cell carcincoma (RCC) in the last decade. This study updated a previously published paper on the economic burden of RCC in the USA by using more recent data to examine the impact of various forms of new oncologic technologies on the economic burden of RCC.